FIELD: chemistry.
SUBSTANCE: invention relates to new a compound of formula I or formula II, or to its pharmaceutically acceptable salts, 
I 
II, where X is S; R1 is H or C1-C6alkyl; R2 is NR5R6; R3 is aryl, substituted with a halogen; R4 is H; R5 is H; R6 is H; R7 is CH2NR8R9 where R8 is H, C1-C10alkyl, C3-C8cycloalkyl, aryl, aryl(C1-C6alkyl), aryl(C2-C6alkenyl), heterocycle(C1-C6alkyl), heterocycle(C2-C6alkenyl), hydroxyl(C1-C6alkyl), hydroxyl(C2-C6alkyl), C1-C6alkoxycarbonyl, aryl(C1-C6alkoxy)carbonyl, carbamoyl(C1-C6alkyl); where the above mentioned aryl is an aromatic ring and is not substituted or substituted with one to three substituting groups, each of which, independently from the others, is chosen from: methylenedioxy, hydroxy, C1-C6-alkoxy, halogen, C1-C6alkyl, trifluoromethyl, trifluoromethoxy, NO2, NH2, NH(C1-C6alkyl), N(C1-C6alkyl)2, NH-acyl, N(C1-C6alkyl)-acyl, hydroxy(C1-C6alkyl), dihydroxy(C1-C6alkyl), CN, C(=O)O(C1-C6alkyl), phenyl, phenyl(C1-C6alkyl), phenyl(C1-C6alkenyl), phenoxy and phenyl(C1-C6alkoxy), R9 is H, C1-C10alkyl, heterocycle(C1-C6alkyl) or heterocycle(C2-C6alkenyl); where the above mentioned heterocycle represents a 5-member saturated monocyclic ring system, consisting of carbon atoms, as well as heteroatoms, chosen from a group comprising N, O, and S, which can be unsubstituted or have one to three substituting groups, independently chosen from a list which includes NO2, aryl(C1-C6alkyl), arylsulphonyl; or R8 and R9 together with nitrogen, to which they are bonded, form a heterocycle, which represents a 5 - 7-member saturated monocyclic ring system, consisting of carbon atoms, as well as one to three heteroatoms, chosen from a group comprising N, O and S, which can be unsubstituted or have one to three substituting groups, independently chosen from a list which includes C1-C6alkoxy, hydroxy, C1-C6alkyl, C2-C6-alkenyl, C(=O)O(C1-C6alkyl), C(=O)NH2, C(=O)NH(C1-C6alkyl), C(=O)N(C1-C6-alkyl)2, hydroxy(C1-C6alkyl), dihydroxy(C2-C6alkyl), aryl, aryl(C1-C6alkyl), aryl(C2-C6alkenyl), aryl(C1-C6alkoxy) and pyrimidin-2-yl; and m equals 0. The invention also relates to a pharmaceutical composition, as well as to use of formula I or formula II compounds.
EFFECT: obtaining new biologically active compounds, with inhibitory properties towards casein kinase 1ε.
32 cl, 3 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| DERIVATIVES OF 3-ARYLTHIOINDOL-2-CARBOXAMIDES AND THEIR ANALOGUES AS INHIBITERS OF CASEIN KINASE Iε | 2005 |
|
RU2391098C2 |
| SUBSTITUTED AMIDES OF THIENOPYRROLECARBOXYLIC ACID, AMIDES OF PYRROLE THIAZOLE CARBOXYLIC ACID AND RELATIVE ANALOGUES AS CASEIN KINASE Iε INHIBITORS | 2005 |
|
RU2403257C2 |
| SUBSTITUTED PYRAZOLES, PHARMACEUTICAL COMPOSITION AND METHOD FOR INHIBITION OF CATHEPSIN S ACTIVITY | 2001 |
|
RU2278863C2 |
| METHOD FOR TREATMENT OF ALLERGY BY USING SUBSTITUTED PYRAZOLES | 2001 |
|
RU2259202C2 |
| N3-ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | 2003 |
|
RU2300528C2 |
| AZAINDOL DERIVATIVES AS FACTOR Xa INHIBITORS | 2004 |
|
RU2330853C2 |
| ANTHRANYLAMIDEPYRIDINE AMIDES WITH SELECTIVE EFFECT AS INHIBITORS OF VEGFR-2 AND VEGFR-3 | 2002 |
|
RU2299208C2 |
| METHOD OF SYNTHESISING DERIVATIVES OF AMINO-METHYL TETRALIN | 2009 |
|
RU2512285C2 |
| SULFUR-CONTAINING COMPOUNDS, METHODS FOR THEIR PREPARING AND PHARMACEUTICAL PREPARATIONS BASED ON THEREOF | 2000 |
|
RU2244708C2 |
| SUBSTITUTED N-PHENYLPYRROLIDINYL METHYLPYRROLIDINE AMIDES AND THERAPEUTIC USE THEREOF AS MODULATORS OF HISTAMINE H3 RECEPTOR | 2008 |
|
RU2477721C2 |
